Research programme: Oragens - Hemispherx Biopharma

Drug Profile

Research programme: Oragens - Hemispherx Biopharma

Alternative Names: Oragens; OragenTM0004

Latest Information Update: 18 Feb 2011

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Hemispherx Biopharma
  • Class Adenine nucleotides; Oligonucleotides
  • Mechanism of Action Hepatitis B virus replication inhibitors; HIV replication inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; HIV infections; Solid tumours; Viral infections

Most Recent Events

  • 19 Aug 2005 This programme is still in active development
  • 18 Sep 2003 Preclinical trials in Solid tumours in USA (PO)
  • 18 Sep 2003 Preclinical trials in HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top